More dilution and faster burn rate. Are they hoping for a quick approval of Azedra so they have an income stream? I have no clue on what potential sales Azedra could bring. Without the Relistor issue resolved favorable, I just see more and more dilution (can you guess I am not a fan of dilution).
Typecheck, I was wondering the same thing, does the Molecular Insights come with any cash? PGNX said there was no debt, but we need to know how much cash they bring. Clearly PGNX is banking of PSMA as being a key prostate cancer and solid tumor marker.
cafisherman, I would like to hear what PGNX has to say about the time frame for Azedra approval and what kind of cash we can expect. I definitely worry more about the cash burn than any dilution from this deal.